Lifevantage Corporation Common Stock (Delaware) (LFVN) — Analysis Summary
Lifevantage Corporation Common Stock (Delaware) (LFVN) has a market cap of $78.22M with year-over-year revenue growth of +14.2%. Net margin stands at 4.3%. The stock trades at a P/E ratio of 13.6.
Key Takeaways
- Revenue changed +14.2% year-over-year
- Net margin of 4.3%
- P/E ratio of 13.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, LFVN posted revenue growth of +14.2% and trades at a P/E of 13.6.
Lifevantage Corporation Common Stock (Delaware) (LFVN)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Revenue declined 14.5% vs the prior period.
Net income fell 41.3% vs the prior period.
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
238
Headquarters
LEHI, UT
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.20
Dividend Yield
3.23%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.